Current status of diagnosis and treatment in patients with high myopia combined with glaucoma
10.3980/j.issn.1672-5123.2026.5.12
- VernacularTitle:高度近视合并青光眼患者的诊断和治疗现状
- Author:
Caiping ZHOU
1
;
Yang LYU
1
Author Information
1. Ophthalmic Center, the 940th Hospital of Joint Service Support Forces of the Chinese People's Liberation Army,Lanzhou 730000,Gansu Province, China; First School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
- Publication Type:Journal Article
- Keywords:
high myopia;
glaucoma;
optical coherence tomography;
stem cell therapy
- From:
International Eye Science
2026;26(5):800-804
- CountryChina
- Language:Chinese
-
Abstract:
High myopia combined with glaucoma(HMG), as a refractory subtype of glaucoma, poses significant challenges due to overlapping structural alterations of both conditions,leading to difficulties in differential diagnosis and a notably high missed diagnosis rate. Optical coherence tomography(OCT)revealed that rapid thinning of the temporal retinal nerve fiber layer is a key biomarker for the early diagnosis of HMG, and reference values for physiological thinning have been established. In addition, artificial intelligence(AI)-assisted diagnostic systems have demonstrated considerable potential in scenarios such as fundus image analysis and data interpretation. Global collaborative initiatives on HMG are currently constructing multicenter databases to support the training and validation of AI models.In terms of treatment, the strategy for intraocular pressure control needs to be further optimized,including setting lower target intraocular pressure, paying attention to medication specificity, while emphasizing neuroprotection and lifestyle interventions. Innovative treatments, including stem cell therapy, have progressed to phase II clinical trials, with some patients exhibiting measurable improvements in visual acuity. Furthermore, individualized management based on disease stratificationis is still required. Future developments are expected to focus on precision medicine, early screening programs, and interdisciplinary collaboration, with the goal of improving visual outcomes in patients with HMG.
